CA3000189A1 - Compositions and methods to treat viral infections - Google Patents
Compositions and methods to treat viral infections Download PDFInfo
- Publication number
- CA3000189A1 CA3000189A1 CA3000189A CA3000189A CA3000189A1 CA 3000189 A1 CA3000189 A1 CA 3000189A1 CA 3000189 A CA3000189 A CA 3000189A CA 3000189 A CA3000189 A CA 3000189A CA 3000189 A1 CA3000189 A1 CA 3000189A1
- Authority
- CA
- Canada
- Prior art keywords
- nuclease
- nucleic acid
- composition
- genome
- cmv
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims abstract description 118
- 239000000203 mixture Substances 0.000 title claims abstract description 80
- 208000036142 Viral infection Diseases 0.000 title abstract description 11
- 230000009385 viral infection Effects 0.000 title abstract description 10
- 101710163270 Nuclease Proteins 0.000 claims abstract description 195
- 108020005004 Guide RNA Proteins 0.000 claims abstract description 166
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 128
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 127
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 127
- 108091033409 CRISPR Proteins 0.000 claims abstract description 108
- 230000003612 virological effect Effects 0.000 claims abstract description 100
- 239000013612 plasmid Substances 0.000 claims abstract description 45
- 210000000056 organ Anatomy 0.000 claims abstract description 35
- 102000004389 Ribonucleoproteins Human genes 0.000 claims abstract description 16
- 108010081734 Ribonucleoproteins Proteins 0.000 claims abstract description 16
- 241000701022 Cytomegalovirus Species 0.000 claims description 97
- 230000008685 targeting Effects 0.000 claims description 74
- 241000700584 Simplexvirus Species 0.000 claims description 73
- 239000013598 vector Substances 0.000 claims description 54
- 238000011282 treatment Methods 0.000 claims description 52
- 238000012384 transportation and delivery Methods 0.000 claims description 41
- 210000001519 tissue Anatomy 0.000 claims description 35
- 239000002502 liposome Substances 0.000 claims description 32
- 208000015181 infectious disease Diseases 0.000 claims description 28
- 239000002105 nanoparticle Substances 0.000 claims description 26
- 230000010076 replication Effects 0.000 claims description 25
- 239000013603 viral vector Substances 0.000 claims description 23
- 229940037201 oris Drugs 0.000 claims description 20
- 238000010459 TALEN Methods 0.000 claims description 18
- 230000005782 double-strand break Effects 0.000 claims description 18
- 230000000295 complement effect Effects 0.000 claims description 16
- 108010017070 Zinc Finger Nucleases Proteins 0.000 claims description 15
- 238000003780 insertion Methods 0.000 claims description 14
- 230000037431 insertion Effects 0.000 claims description 14
- 241001430294 unidentified retrovirus Species 0.000 claims description 14
- 241000713666 Lentivirus Species 0.000 claims description 12
- 210000003754 fetus Anatomy 0.000 claims description 11
- 210000004072 lung Anatomy 0.000 claims description 11
- 241000702421 Dependoparvovirus Species 0.000 claims description 10
- -1 cationic lipid Chemical class 0.000 claims description 10
- 241000701161 unidentified adenovirus Species 0.000 claims description 10
- 239000002202 Polyethylene glycol Substances 0.000 claims description 9
- 229920001223 polyethylene glycol Polymers 0.000 claims description 9
- 241001529453 unidentified herpesvirus Species 0.000 claims description 9
- 241000710929 Alphavirus Species 0.000 claims description 8
- 241000700618 Vaccinia virus Species 0.000 claims description 8
- 229920006317 cationic polymer Polymers 0.000 claims description 8
- 102000020313 Cell-Penetrating Peptides Human genes 0.000 claims description 7
- 108010051109 Cell-Penetrating Peptides Proteins 0.000 claims description 7
- 210000002216 heart Anatomy 0.000 claims description 7
- 238000001727 in vivo Methods 0.000 claims description 7
- 239000002073 nanorod Substances 0.000 claims description 7
- 230000009870 specific binding Effects 0.000 claims description 7
- 229940100613 topical solution Drugs 0.000 claims description 6
- 210000003734 kidney Anatomy 0.000 claims description 5
- 210000004185 liver Anatomy 0.000 claims description 5
- 210000000496 pancreas Anatomy 0.000 claims description 5
- 230000000699 topical effect Effects 0.000 claims description 5
- 210000000936 intestine Anatomy 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 3
- 210000001541 thymus gland Anatomy 0.000 claims description 3
- 210000001508 eye Anatomy 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 abstract description 82
- 108020004999 messenger RNA Proteins 0.000 abstract description 7
- 108010040467 CRISPR-Associated Proteins Proteins 0.000 abstract description 3
- 210000004027 cell Anatomy 0.000 description 217
- 108020004414 DNA Proteins 0.000 description 73
- 241000700605 Viruses Species 0.000 description 43
- 102000004169 proteins and genes Human genes 0.000 description 42
- 238000012217 deletion Methods 0.000 description 30
- 230000037430 deletion Effects 0.000 description 30
- 238000001890 transfection Methods 0.000 description 26
- 102000040430 polynucleotide Human genes 0.000 description 22
- 108091033319 polynucleotide Proteins 0.000 description 22
- 239000002157 polynucleotide Substances 0.000 description 22
- 238000003776 cleavage reaction Methods 0.000 description 20
- 230000007017 scission Effects 0.000 description 20
- 230000000694 effects Effects 0.000 description 19
- 230000027455 binding Effects 0.000 description 18
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 17
- 239000003814 drug Substances 0.000 description 17
- 230000014509 gene expression Effects 0.000 description 17
- 108091093088 Amplicon Proteins 0.000 description 16
- 108010042407 Endonucleases Proteins 0.000 description 15
- 108091079001 CRISPR RNA Proteins 0.000 description 14
- 238000003556 assay Methods 0.000 description 14
- 238000010362 genome editing Methods 0.000 description 14
- 238000000338 in vitro Methods 0.000 description 14
- 150000002632 lipids Chemical class 0.000 description 14
- 239000002773 nucleotide Substances 0.000 description 14
- 125000003729 nucleotide group Chemical group 0.000 description 14
- 102000004190 Enzymes Human genes 0.000 description 13
- 108090000790 Enzymes Proteins 0.000 description 13
- 101150038500 cas9 gene Proteins 0.000 description 13
- 230000004663 cell proliferation Effects 0.000 description 13
- 229940079593 drug Drugs 0.000 description 13
- 230000006870 function Effects 0.000 description 13
- 230000006378 damage Effects 0.000 description 12
- 230000029087 digestion Effects 0.000 description 12
- 239000000463 material Substances 0.000 description 12
- 102100031780 Endonuclease Human genes 0.000 description 11
- 230000006907 apoptotic process Effects 0.000 description 11
- 238000013461 design Methods 0.000 description 11
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 11
- 230000008439 repair process Effects 0.000 description 11
- 108010043645 Transcription Activator-Like Effector Nucleases Proteins 0.000 description 10
- 230000001225 therapeutic effect Effects 0.000 description 10
- 238000013518 transcription Methods 0.000 description 10
- 238000002604 ultrasonography Methods 0.000 description 10
- 238000009472 formulation Methods 0.000 description 9
- 239000002245 particle Substances 0.000 description 9
- 238000003753 real-time PCR Methods 0.000 description 9
- 230000035897 transcription Effects 0.000 description 9
- 238000002054 transplantation Methods 0.000 description 9
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 8
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 8
- 101150059079 EBNA1 gene Proteins 0.000 description 8
- 208000009889 Herpes Simplex Diseases 0.000 description 8
- 108091028113 Trans-activating crRNA Proteins 0.000 description 8
- 239000012634 fragment Substances 0.000 description 8
- 208000011691 Burkitt lymphomas Diseases 0.000 description 7
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 7
- 239000012528 membrane Substances 0.000 description 7
- 229920000642 polymer Polymers 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 229910052725 zinc Inorganic materials 0.000 description 7
- 239000011701 zinc Substances 0.000 description 7
- 206010011831 Cytomegalovirus infection Diseases 0.000 description 6
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 6
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 6
- 108020005091 Replication Origin Proteins 0.000 description 6
- 101150003185 US12 gene Proteins 0.000 description 6
- 125000002091 cationic group Chemical group 0.000 description 6
- 239000000306 component Substances 0.000 description 6
- 238000013270 controlled release Methods 0.000 description 6
- 230000003247 decreasing effect Effects 0.000 description 6
- 238000012377 drug delivery Methods 0.000 description 6
- 230000006801 homologous recombination Effects 0.000 description 6
- 238000002744 homologous recombination Methods 0.000 description 6
- 230000002452 interceptive effect Effects 0.000 description 6
- 238000001638 lipofection Methods 0.000 description 6
- 230000007246 mechanism Effects 0.000 description 6
- 230000037361 pathway Effects 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 108091008146 restriction endonucleases Proteins 0.000 description 6
- 108090000672 Annexin A5 Proteins 0.000 description 5
- 102000004121 Annexin A5 Human genes 0.000 description 5
- 108050006685 Apoptosis regulator BAX Proteins 0.000 description 5
- 238000000116 DAPI staining Methods 0.000 description 5
- 241000701074 Human alphaherpesvirus 2 Species 0.000 description 5
- 208000032420 Latent Infection Diseases 0.000 description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 description 5
- 230000001640 apoptogenic effect Effects 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 238000005520 cutting process Methods 0.000 description 5
- 231100000433 cytotoxic Toxicity 0.000 description 5
- 230000001472 cytotoxic effect Effects 0.000 description 5
- 230000034994 death Effects 0.000 description 5
- 238000007847 digital PCR Methods 0.000 description 5
- 239000000539 dimer Substances 0.000 description 5
- 230000034431 double-strand break repair via homologous recombination Effects 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 210000002950 fibroblast Anatomy 0.000 description 5
- 238000000684 flow cytometry Methods 0.000 description 5
- 230000014726 immortalization of host cell Effects 0.000 description 5
- 229910052751 metal Inorganic materials 0.000 description 5
- 239000002184 metal Substances 0.000 description 5
- 230000035755 proliferation Effects 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 238000007480 sanger sequencing Methods 0.000 description 5
- 102100027308 Apoptosis regulator BAX Human genes 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 4
- 238000010453 CRISPR/Cas method Methods 0.000 description 4
- 102000004533 Endonucleases Human genes 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 102100034343 Integrase Human genes 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 230000030833 cell death Effects 0.000 description 4
- 231100000135 cytotoxicity Toxicity 0.000 description 4
- 230000003013 cytotoxicity Effects 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 238000000386 microscopy Methods 0.000 description 4
- 239000000178 monomer Substances 0.000 description 4
- 230000007935 neutral effect Effects 0.000 description 4
- 229920000575 polymersome Polymers 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 230000009897 systematic effect Effects 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 238000011144 upstream manufacturing Methods 0.000 description 4
- 210000004291 uterus Anatomy 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- 230000029812 viral genome replication Effects 0.000 description 4
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 3
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 3
- 102100032305 Bcl-2 homologous antagonist/killer Human genes 0.000 description 3
- 201000004569 Blindness Diseases 0.000 description 3
- 108091026890 Coding region Proteins 0.000 description 3
- 102000053602 DNA Human genes 0.000 description 3
- 230000033616 DNA repair Effects 0.000 description 3
- 230000004568 DNA-binding Effects 0.000 description 3
- 241000252212 Danio rerio Species 0.000 description 3
- 206010011878 Deafness Diseases 0.000 description 3
- 108700024394 Exon Proteins 0.000 description 3
- 102000004962 Voltage-dependent anion channels Human genes 0.000 description 3
- 108090001129 Voltage-dependent anion channels Proteins 0.000 description 3
- 101150063416 add gene Proteins 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 210000000349 chromosome Anatomy 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 238000005538 encapsulation Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 230000010370 hearing loss Effects 0.000 description 3
- 208000016354 hearing loss disease Diseases 0.000 description 3
- 230000010354 integration Effects 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 230000002101 lytic effect Effects 0.000 description 3
- 230000002438 mitochondrial effect Effects 0.000 description 3
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 210000002569 neuron Anatomy 0.000 description 3
- 230000035699 permeability Effects 0.000 description 3
- 150000003904 phospholipids Chemical class 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 238000003908 quality control method Methods 0.000 description 3
- 230000008263 repair mechanism Effects 0.000 description 3
- 230000003252 repetitive effect Effects 0.000 description 3
- 230000003362 replicative effect Effects 0.000 description 3
- 230000001177 retroviral effect Effects 0.000 description 3
- 230000005783 single-strand break Effects 0.000 description 3
- 230000009295 sperm incapacitation Effects 0.000 description 3
- 238000012385 systemic delivery Methods 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 102100027211 Albumin Human genes 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 101710092462 Alpha-hemolysin Proteins 0.000 description 2
- 108091012583 BCL2 Proteins 0.000 description 2
- 102100021895 Bcl-2-like protein 13 Human genes 0.000 description 2
- 102100022541 Bcl-2-related ovarian killer protein Human genes 0.000 description 2
- 102100030497 Cytochrome c Human genes 0.000 description 2
- 108010075031 Cytochromes c Proteins 0.000 description 2
- 230000007018 DNA scission Effects 0.000 description 2
- 108060002716 Exonuclease Proteins 0.000 description 2
- 208000029433 Herpesviridae infectious disease Diseases 0.000 description 2
- 101100325746 Homo sapiens BAK1 gene Proteins 0.000 description 2
- 101000899346 Homo sapiens Bcl-2-related ovarian killer protein Proteins 0.000 description 2
- 238000009015 Human TaqMan MicroRNA Assay kit Methods 0.000 description 2
- 241000701069 Human herpesvirus 2 strain G Species 0.000 description 2
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 2
- 108010061833 Integrases Proteins 0.000 description 2
- 108091092195 Intron Proteins 0.000 description 2
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
- 206010027374 Mental impairment Diseases 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
- 108090000848 Ubiquitin Proteins 0.000 description 2
- 102000044159 Ubiquitin Human genes 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000003044 adaptive effect Effects 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 230000003622 anti-hsv Effects 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 230000005775 apoptotic pathway Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 210000004436 artificial bacterial chromosome Anatomy 0.000 description 2
- 210000001106 artificial yeast chromosome Anatomy 0.000 description 2
- 230000008970 bacterial immunity Effects 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 239000012503 blood component Substances 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 230000032823 cell division Effects 0.000 description 2
- 230000022534 cell killing Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000002759 chromosomal effect Effects 0.000 description 2
- 210000004087 cornea Anatomy 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 231100000263 cytotoxicity test Toxicity 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 208000037771 disease arising from reactivation of latent virus Diseases 0.000 description 2
- 230000011559 double-strand break repair via nonhomologous end joining Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 102000013165 exonuclease Human genes 0.000 description 2
- 238000007667 floating Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 238000013412 genome amplification Methods 0.000 description 2
- 230000007440 host cell apoptosis Effects 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 238000010874 in vitro model Methods 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 239000002122 magnetic nanoparticle Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000011859 microparticle Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000006780 non-homologous end joining Effects 0.000 description 2
- 238000010606 normalization Methods 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 230000014207 opsonization Effects 0.000 description 2
- 210000002826 placenta Anatomy 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 230000000392 somatic effect Effects 0.000 description 2
- 230000004393 visual impairment Effects 0.000 description 2
- OPCHFPHZPIURNA-MFERNQICSA-N (2s)-2,5-bis(3-aminopropylamino)-n-[2-(dioctadecylamino)acetyl]pentanamide Chemical compound CCCCCCCCCCCCCCCCCCN(CC(=O)NC(=O)[C@H](CCCNCCCN)NCCCN)CCCCCCCCCCCCCCCCCC OPCHFPHZPIURNA-MFERNQICSA-N 0.000 description 1
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 description 1
- SNKAWJBJQDLSFF-NVKMUCNASA-N 1,2-dioleoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC SNKAWJBJQDLSFF-NVKMUCNASA-N 0.000 description 1
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
- BIABMEZBCHDPBV-MPQUPPDSSA-N 1,2-palmitoyl-sn-glycero-3-phospho-(1'-sn-glycerol) Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@@H](O)CO)OC(=O)CCCCCCCCCCCCCCC BIABMEZBCHDPBV-MPQUPPDSSA-N 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- 108010063104 Apoptosis Regulatory Proteins Proteins 0.000 description 1
- 102000010565 Apoptosis Regulatory Proteins Human genes 0.000 description 1
- 102100021893 Apoptosis facilitator Bcl-2-like protein 14 Human genes 0.000 description 1
- 102000019300 Apoptosis regulator BAX Human genes 0.000 description 1
- 108091032955 Bacterial small RNA Proteins 0.000 description 1
- 101150046345 Bak1 gene Proteins 0.000 description 1
- 102100026596 Bcl-2-like protein 1 Human genes 0.000 description 1
- 102100021590 Bcl-2-like protein 10 Human genes 0.000 description 1
- 108091010858 Bcl-2-like protein 13 Proteins 0.000 description 1
- 102100023932 Bcl-2-like protein 2 Human genes 0.000 description 1
- 102100021334 Bcl-2-related protein A1 Human genes 0.000 description 1
- 101150008012 Bcl2l1 gene Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 101100455063 Caenorhabditis elegans lmp-1 gene Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 206010061764 Chromosomal deletion Diseases 0.000 description 1
- 208000016718 Chromosome Inversion Diseases 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 108010041986 DNA Vaccines Proteins 0.000 description 1
- 238000007399 DNA isolation Methods 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 229940021995 DNA vaccine Drugs 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 102000011750 Endodeoxyribonucleases Human genes 0.000 description 1
- 108010037179 Endodeoxyribonucleases Proteins 0.000 description 1
- 206010048554 Endothelial dysfunction Diseases 0.000 description 1
- 206010015866 Extravasation Diseases 0.000 description 1
- 102100022116 F-box only protein 2 Human genes 0.000 description 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
- 229920002306 Glycocalyx Polymers 0.000 description 1
- 208000037952 HSV-1 infection Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 208000001688 Herpes Genitalis Diseases 0.000 description 1
- MAJYPBAJPNUFPV-BQBZGAKWSA-N His-Cys Chemical compound SC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CN=CN1 MAJYPBAJPNUFPV-BQBZGAKWSA-N 0.000 description 1
- 101000971069 Homo sapiens Apoptosis facilitator Bcl-2-like protein 14 Proteins 0.000 description 1
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 1
- 101000798320 Homo sapiens Bcl-2 homologous antagonist/killer Proteins 0.000 description 1
- 101000971082 Homo sapiens Bcl-2-like protein 10 Proteins 0.000 description 1
- 101000971074 Homo sapiens Bcl-2-like protein 13 Proteins 0.000 description 1
- 101000904691 Homo sapiens Bcl-2-like protein 2 Proteins 0.000 description 1
- 101000894929 Homo sapiens Bcl-2-related protein A1 Proteins 0.000 description 1
- 101000824158 Homo sapiens F-box only protein 2 Proteins 0.000 description 1
- 101001056180 Homo sapiens Induced myeloid leukemia cell differentiation protein Mcl-1 Proteins 0.000 description 1
- 241000701085 Human alphaherpesvirus 3 Species 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 241000341655 Human papillomavirus type 16 Species 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 102100026539 Induced myeloid leukemia cell differentiation protein Mcl-1 Human genes 0.000 description 1
- 101150113776 LMP1 gene Proteins 0.000 description 1
- 101710097665 Leucine aminopeptidase 1 Proteins 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 239000012097 Lipofectamine 2000 Substances 0.000 description 1
- 208000036626 Mental retardation Diseases 0.000 description 1
- 241000713869 Moloney murine leukemia virus Species 0.000 description 1
- 208000034486 Multi-organ failure Diseases 0.000 description 1
- 108091061960 Naked DNA Proteins 0.000 description 1
- 108020004485 Nonsense Codon Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 206010067152 Oral herpes Diseases 0.000 description 1
- 206010053159 Organ failure Diseases 0.000 description 1
- 108091006006 PEGylated Proteins Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229920002873 Polyethylenimine Polymers 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 101710082688 Probable leucine aminopeptidase 1 Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 101710195674 Replication initiator protein Proteins 0.000 description 1
- 206010038848 Retinal detachment Diseases 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 241000193996 Streptococcus pyogenes Species 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 102100033082 TNF receptor-associated factor 3 Human genes 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 101710185494 Zinc finger protein Proteins 0.000 description 1
- 102100023597 Zinc finger protein 816 Human genes 0.000 description 1
- DSNRWDQKZIEDDB-GCMPNPAFSA-N [(2r)-3-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-2-[(z)-octadec-9-enoyl]oxypropyl] (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C/CCCCCCCC DSNRWDQKZIEDDB-GCMPNPAFSA-N 0.000 description 1
- HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000012574 advanced DMEM Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 229940045799 anthracyclines and related substance Drugs 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 101150024147 bax gene Proteins 0.000 description 1
- 102000055102 bcl-2-Associated X Human genes 0.000 description 1
- 108700000707 bcl-2-Associated X Proteins 0.000 description 1
- 108700000711 bcl-X Proteins 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 238000000339 bright-field microscopy Methods 0.000 description 1
- 238000009933 burial Methods 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- 239000002041 carbon nanotube Substances 0.000 description 1
- 229910021393 carbon nanotube Inorganic materials 0.000 description 1
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 description 1
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 229930183167 cerebroside Natural products 0.000 description 1
- 150000001784 cerebrosides Chemical class 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 239000012829 chemotherapy agent Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000002716 delivery method Methods 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 239000000412 dendrimer Substances 0.000 description 1
- 229920000736 dendritic polymer Polymers 0.000 description 1
- 230000000368 destabilizing effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000002961 echo contrast media Substances 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 230000008694 endothelial dysfunction Effects 0.000 description 1
- 238000012407 engineering method Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000036251 extravasation Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 108091006047 fluorescent proteins Proteins 0.000 description 1
- 102000034287 fluorescent proteins Human genes 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 210000000609 ganglia Anatomy 0.000 description 1
- 150000002270 gangliosides Chemical class 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000001476 gene delivery Methods 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 230000009395 genetic defect Effects 0.000 description 1
- 201000004946 genital herpes Diseases 0.000 description 1
- 210000004517 glycocalyx Anatomy 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 231100000888 hearing loss Toxicity 0.000 description 1
- 210000003709 heart valve Anatomy 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 230000007446 host cell death Effects 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- CPSYWNLKRDURMG-UHFFFAOYSA-L hydron;manganese(2+);phosphate Chemical compound [Mn+2].OP([O-])([O-])=O CPSYWNLKRDURMG-UHFFFAOYSA-L 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- 230000037451 immune surveillance Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000017730 intein-mediated protein splicing Effects 0.000 description 1
- 230000010039 intracellular degradation Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 235000013980 iron oxide Nutrition 0.000 description 1
- 210000001865 kupffer cell Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- GVALZJMUIHGIMD-UHFFFAOYSA-H magnesium phosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O GVALZJMUIHGIMD-UHFFFAOYSA-H 0.000 description 1
- 239000004137 magnesium phosphate Substances 0.000 description 1
- 229910000157 magnesium phosphate Inorganic materials 0.000 description 1
- 229960002261 magnesium phosphate Drugs 0.000 description 1
- 235000010994 magnesium phosphates Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 210000001700 mitochondrial membrane Anatomy 0.000 description 1
- NKAAEMMYHLFEFN-UHFFFAOYSA-M monosodium tartrate Chemical compound [Na+].OC(=O)C(O)C(O)C([O-])=O NKAAEMMYHLFEFN-UHFFFAOYSA-M 0.000 description 1
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 229940127073 nucleoside analogue Drugs 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 244000000042 obligate parasite Species 0.000 description 1
- 230000009437 off-target effect Effects 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 210000002990 parathyroid gland Anatomy 0.000 description 1
- 229940046159 pegylated liposomal doxorubicin Drugs 0.000 description 1
- 230000006320 pegylation Effects 0.000 description 1
- 230000008823 permeabilization Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 150000008105 phosphatidylcholines Chemical class 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- 229940067605 phosphatidylethanolamines Drugs 0.000 description 1
- 150000008106 phosphatidylserines Chemical class 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000001566 pro-viral effect Effects 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 229960003712 propranolol Drugs 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 239000002096 quantum dot Substances 0.000 description 1
- 229910052761 rare earth metal Inorganic materials 0.000 description 1
- 150000002910 rare earth metals Chemical class 0.000 description 1
- 230000036647 reaction Effects 0.000 description 1
- 230000007420 reactivation Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 230000004264 retinal detachment Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 102000014452 scavenger receptors Human genes 0.000 description 1
- 108010078070 scavenger receptors Proteins 0.000 description 1
- 108091006024 signal transducing proteins Proteins 0.000 description 1
- 102000034285 signal transducing proteins Human genes 0.000 description 1
- 229940126586 small molecule drug Drugs 0.000 description 1
- 235000012237 sodium aluminium phosphate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 150000003408 sphingolipids Chemical class 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000009121 systemic therapy Methods 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 238000013271 transdermal drug delivery Methods 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000003151 transfection method Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000001296 transplacental effect Effects 0.000 description 1
- 238000011277 treatment modality Methods 0.000 description 1
- IQQWMJSNEUUJAY-UHFFFAOYSA-D trialuminum;sodium;dihydrogen phosphate;hydrogen phosphate;tetrahydrate Chemical compound O.O.O.O.[Na+].[Al+3].[Al+3].[Al+3].OP(O)([O-])=O.OP(O)([O-])=O.OP(O)([O-])=O.OP(O)([O-])=O.OP(O)([O-])=O.OP(O)([O-])=O.OP([O-])([O-])=O.OP([O-])([O-])=O IQQWMJSNEUUJAY-UHFFFAOYSA-D 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 231100000588 tumorigenic Toxicity 0.000 description 1
- 230000000381 tumorigenic effect Effects 0.000 description 1
- 238000010396 two-hybrid screening Methods 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 238000011311 validation assay Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000006490 viral transcription Effects 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 239000000277 virosome Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562168259P | 2015-05-29 | 2015-05-29 | |
| US201562168262P | 2015-05-29 | 2015-05-29 | |
| US62/168,262 | 2015-05-29 | ||
| US62/168,259 | 2015-05-29 | ||
| PCT/US2016/034606 WO2016196273A1 (en) | 2015-05-29 | 2016-05-27 | Compositions and methods to treat viral infections |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3000189A1 true CA3000189A1 (en) | 2016-12-08 |
Family
ID=57441664
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3000189A Abandoned CA3000189A1 (en) | 2015-05-29 | 2016-05-27 | Compositions and methods to treat viral infections |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP3331571A4 (enExample) |
| JP (1) | JP2018516983A (enExample) |
| CA (1) | CA3000189A1 (enExample) |
| WO (1) | WO2016196273A1 (enExample) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013066438A2 (en) | 2011-07-22 | 2013-05-10 | President And Fellows Of Harvard College | Evaluation and improvement of nuclease cleavage specificity |
| US9163284B2 (en) | 2013-08-09 | 2015-10-20 | President And Fellows Of Harvard College | Methods for identifying a target site of a Cas9 nuclease |
| US9359599B2 (en) | 2013-08-22 | 2016-06-07 | President And Fellows Of Harvard College | Engineered transcription activator-like effector (TALE) domains and uses thereof |
| US9340799B2 (en) | 2013-09-06 | 2016-05-17 | President And Fellows Of Harvard College | MRNA-sensing switchable gRNAs |
| US9322037B2 (en) | 2013-09-06 | 2016-04-26 | President And Fellows Of Harvard College | Cas9-FokI fusion proteins and uses thereof |
| US9526784B2 (en) | 2013-09-06 | 2016-12-27 | President And Fellows Of Harvard College | Delivery system for functional nucleases |
| US20150166984A1 (en) | 2013-12-12 | 2015-06-18 | President And Fellows Of Harvard College | Methods for correcting alpha-antitrypsin point mutations |
| AU2015298571B2 (en) | 2014-07-30 | 2020-09-03 | President And Fellows Of Harvard College | Cas9 proteins including ligand-dependent inteins |
| EP3324999A1 (en) * | 2015-05-29 | 2018-05-30 | Agenovir Corporation | Compositions and methods for cell targeted hpv treatment |
| WO2017070632A2 (en) | 2015-10-23 | 2017-04-27 | President And Fellows Of Harvard College | Nucleobase editors and uses thereof |
| WO2018027078A1 (en) | 2016-08-03 | 2018-02-08 | President And Fellows Of Harard College | Adenosine nucleobase editors and uses thereof |
| AU2017308889B2 (en) | 2016-08-09 | 2023-11-09 | President And Fellows Of Harvard College | Programmable Cas9-recombinase fusion proteins and uses thereof |
| WO2018039438A1 (en) | 2016-08-24 | 2018-03-01 | President And Fellows Of Harvard College | Incorporation of unnatural amino acids into proteins using base editing |
| KR20240007715A (ko) | 2016-10-14 | 2024-01-16 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 핵염기 에디터의 aav 전달 |
| WO2018119359A1 (en) | 2016-12-23 | 2018-06-28 | President And Fellows Of Harvard College | Editing of ccr5 receptor gene to protect against hiv infection |
| WO2018165504A1 (en) | 2017-03-09 | 2018-09-13 | President And Fellows Of Harvard College | Suppression of pain by gene editing |
| KR20190123328A (ko) | 2017-03-09 | 2019-10-31 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 암 백신 |
| CN110914310A (zh) | 2017-03-10 | 2020-03-24 | 哈佛大学的校长及成员们 | 胞嘧啶至鸟嘌呤碱基编辑器 |
| IL306092A (en) | 2017-03-23 | 2023-11-01 | Harvard College | Nucleic base editors that include nucleic acid programmable DNA binding proteins |
| US11560566B2 (en) | 2017-05-12 | 2023-01-24 | President And Fellows Of Harvard College | Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation |
| EP3658573A1 (en) | 2017-07-28 | 2020-06-03 | President and Fellows of Harvard College | Methods and compositions for evolving base editors using phage-assisted continuous evolution (pace) |
| EP3676376B1 (en) | 2017-08-30 | 2025-01-15 | President and Fellows of Harvard College | High efficiency base editors comprising gam |
| CA3082251A1 (en) | 2017-10-16 | 2019-04-25 | The Broad Institute, Inc. | Uses of adenosine base editors |
| US12406749B2 (en) | 2017-12-15 | 2025-09-02 | The Broad Institute, Inc. | Systems and methods for predicting repair outcomes in genetic engineering |
| CN112654710A (zh) | 2018-05-16 | 2021-04-13 | 辛瑟高公司 | 用于指导rna设计和使用的方法和系统 |
| WO2019226953A1 (en) | 2018-05-23 | 2019-11-28 | The Broad Institute, Inc. | Base editors and uses thereof |
| EP3820495A4 (en) | 2018-07-09 | 2022-07-20 | The Broad Institute Inc. | RNA-PROGRAMMABLE EPIGENETIC RNA MODIFIERS AND THEIR USES |
| WO2020092453A1 (en) | 2018-10-29 | 2020-05-07 | The Broad Institute, Inc. | Nucleobase editors comprising geocas9 and uses thereof |
| US12351837B2 (en) | 2019-01-23 | 2025-07-08 | The Broad Institute, Inc. | Supernegatively charged proteins and uses thereof |
| WO2020191241A1 (en) | 2019-03-19 | 2020-09-24 | The Broad Institute, Inc. | Methods and compositions for editing nucleotide sequences |
| WO2020214842A1 (en) | 2019-04-17 | 2020-10-22 | The Broad Institute, Inc. | Adenine base editors with reduced off-target effects |
| US12435330B2 (en) | 2019-10-10 | 2025-10-07 | The Broad Institute, Inc. | Methods and compositions for prime editing RNA |
| CA3177481A1 (en) | 2020-05-08 | 2021-11-11 | David R. Liu | Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence |
| EP4179085A1 (en) * | 2020-07-07 | 2023-05-17 | Oriengene Biotechnology Ltd | Guide rna for hsv-1 gene editing and method thereof |
| EP4281184A4 (en) * | 2021-01-25 | 2025-04-30 | Fred Hutchinson Cancer Center | TREATMENT OF HSV-1 USING A MEGANUCLEASE |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20150098954A1 (en) * | 2013-10-08 | 2015-04-09 | Elwha Llc | Compositions and Methods Related to CRISPR Targeting |
-
2016
- 2016-05-27 JP JP2018513744A patent/JP2018516983A/ja active Pending
- 2016-05-27 EP EP16804107.7A patent/EP3331571A4/en not_active Withdrawn
- 2016-05-27 CA CA3000189A patent/CA3000189A1/en not_active Abandoned
- 2016-05-27 WO PCT/US2016/034606 patent/WO2016196273A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| EP3331571A4 (en) | 2019-04-10 |
| JP2018516983A (ja) | 2018-06-28 |
| EP3331571A1 (en) | 2018-06-13 |
| WO2016196273A1 (en) | 2016-12-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10117911B2 (en) | Compositions and methods to treat herpes simplex virus infections | |
| US20160346362A1 (en) | Methods and compositions for treating cytomegalovirus infections | |
| US10066241B2 (en) | Compositions and methods of delivering treatments for latent viral infections | |
| EP3331571A1 (en) | Compositions and methods to treat viral infections | |
| US20190201501A1 (en) | Compositions and methods for cell targeted hpv treatment | |
| US20170088587A1 (en) | Antiviral fusion proteins and genes | |
| US20160348074A1 (en) | Methods and compositions for treating cells for transplant | |
| US20170247703A1 (en) | Antiviral nuclease methods | |
| US20170247690A1 (en) | Oncoviral treatment with nuclease and chemotherapeutic | |
| JP2018516983A5 (enExample) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |
Effective date: 20220301 |